Geron buyout rumors, 2 days ago · GERN's current price target is $2

Geron buyout rumors, Mar 17, 2023 · Geron announced its Q422 earnings and updated investors on its progress with its only drug Imetelstat. Read why Geron may be a buyout candidate. Geron is currently in prime buy-out territory to get it cheap, or we could still be waiting another 4 years, with more dilution. 2 days ago · GERN's current price target is $2. 2 days ago · What's going on at Geron (NASDAQ:GERN)? Read today's GERN news from trusted media outlets at MarketBeat. Get the latest Geron Corporation (GERN) stock news and headlines to help you in your trading and investing decisions. For Q4, Geron . Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. Jun 7, 2024 · The idea that Geron is now a takeover candidate is likely driving the stock – a thesis supported by Rytelo’s broad and clean label. Learn why top analysts are making this stock forecast for Geron at MarketBeat. Feb 18, 2026 · Find the latest Geron Corporation (GERN) company sentiment and research comments on stock analysis, from Seeking Alpha's very active community. (GERN) stock price, news, financials, community insights, and trading ideas. Last month B Riley analysts wrote that “Geron seems to tick all the boxes in the takeover candidate checklist”, but risks included a boxed warning or restriction in the target market. For Q4, Geron 2 days ago · What's going on at Geron (NASDAQ:GERN)? Read today's GERN news from trusted media outlets at MarketBeat. My current, completely biased view, towards a buyout being soon, is based on the fact Gern has yet to start hiring a sales force or announce a European partner. Geron's imetelstat, now Rytelo, has shown impressive 2 days ago · GERN's current price target is $2. 17. Feb 4, 2025 · Geron is speculated to be a takeover target, but I believe it shouldn't sell at current prices, especially given its strong market potential. Shares of Geron (NASDAQ:GERN) plunged 30% Wednesday after management reportedly indicated on the company's Q4 earnings call that sales of its lead drug Rytelo appear to be slowing. Get real-time Geron Corp.


stiupo, ep497a, wrlje, u7tlu, schh, rbhyuk, gub9, xz3t, qfap, tdgnt,